Makers Laboratories Limited
MAKERSL.BO
Bombay Stock Exchange155.00
INR
-3.45
- -
ISIN
INE987A01010
Return %
Stock
S&P500
1Y
-1.02
26.53
3Y
44.45
76.60
5Y
-37.35
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Saahil U. Parikh
- Full Time Employees
- 121
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 54-D, Kandivli Industrial Estate Mumbai India
- IPO Date
- Dec 30, 2024
- Website
- makerslabs.com
- Similar Companies
- Business
- Makers Laboratories Limited is an Indian pharmaceutical company specializing in the manufacturing and marketing of pharmaceutical formulations and drug intermediates. Its product portfolio includes tablets, capsules, liquids, injectables, creams, and ointments, with key brands such as Duramol (Paracetamol), Artemak-AB (α-β Arteether), Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (cough remedies), and Exylin (Amoxycillin range). The company operates primarily in India and focuses on branded generics across a wide range of general health therapeutic segments. Founded in 1984 and headquartered in Mumbai, Maharashtra, Makers Laboratories maintains a strong supply chain with significant operations in formulation drugs and drug intermediates. In recent years, Makers Laboratories has undergone significant strategic expansion through the acquisition of a controlling stake in Resonance Specialties Limited in 2020, facilitating its entry into specialty chemicals, active pharmaceutical ingredients (API), and drug intermediates businesses that complement its generic formulations. It has also upgraded and modernized its manufacturing plants, including capacity enhancement and the launch of new ophthalmic products at the Naroda facility in Ahmedabad. The company has continued to report steady growth in sales and operational efficiency, supported by a robust distribution network across India and a strong vendor/supplier base. Makers Laboratories extends its pharmaceutical offerings through segments such as analgesics, anti-infectives, anti-malarials, anti-inflammatory drugs, and respiratory care. Its manufacturing facilities cover solid dosage forms, liquid formulations, injectables, and dermatological products. The company also offers supplementary products like nutritional malt preparations. Recent operational improvements include enhancements in the liquid injectable manufacturing unit and introduction of new product lines aimed at broadening the therapeutic coverage and market presence. Overall, Makers Laboratories Limited is positioned as a comprehensive pharmaceutical manufacturer with diversified product categories spanning branded generics, APIs, and specialty chemicals, supported by recent acquisitions and facility upgrades that underline its strategic intent to strengthen its footprint in the Indian pharmaceutical industry and related chemical sectors.